BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29661164)

  • 21. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC.
    Grimminger PP; Maus MK; Schneider PM; Metzger R; Hölscher AH; Sugita H; Danenberg PV; Alakus H; Brabender J
    Lung Cancer; 2012 Oct; 78(1):87-91. PubMed ID: 22884253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
    Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
    BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
    Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
    Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.
    Glubb DM; Paré-Brunet L; Jantus-Lewintre E; Jiang C; Crona D; Etheridge AS; Mirza O; Zhang W; Seiser EL; Rzyman W; Jassem J; Auman T; Hirsch FR; Owzar K; Camps C; Dziadziuszko R; Innocenti F
    J Thorac Oncol; 2015 Jul; 10(7):1067-75. PubMed ID: 26134224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
    Vinayanuwattikun C; Chantranuwat P; Sriuranpong V; Mutirangura A
    Int J Clin Oncol; 2014 Aug; 19(4):586-92. PubMed ID: 23824557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
    Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
    Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence.
    Herbst A; Wallner M; Rahmig K; Stieber P; Crispin A; Lamerz R; Kolligs FT
    Eur J Gastroenterol Hepatol; 2009 May; 21(5):565-9. PubMed ID: 19282772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.
    Dragoj M; Milosevic Z; Bankovic J; Dinic J; Pesic M; Tanic N; Stankovic T
    Tumour Biol; 2015 Nov; 36(11):8773-80. PubMed ID: 26055143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
    Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M
    Oncology; 2018; 94(5):311-323. PubMed ID: 29533963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Akiba T; Morikawa T; Odaka M; Nakada T; Kamiya N; Yamashita M; Yabe M; Inagaki T; Asano H; Mori S; Tsukamoto Y; Urashima M
    Clin Cancer Res; 2018 Sep; 24(17):4089-4097. PubMed ID: 30018118
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression.
    Jiang W; Fan H; Qian C; Ding J; Wang Q; Pang X
    BMC Cancer; 2016 Jan; 16():16. PubMed ID: 26758745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
    Malentacchi F; Simi L; Nannelli C; Andreani M; Janni A; Pastorekova S; Orlando C
    Lung Cancer; 2009 Jun; 64(3):271-6. PubMed ID: 19022520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.
    Jiang W; Pang XG; Wang Q; Shen YX; Chen XK; Xi JJ
    Clin Lung Cancer; 2012 Jul; 13(4):280-7. PubMed ID: 22178381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
    Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer.
    Ferraro B; Bepler G; Sharma S; Cantor A; Haura EB
    J Clin Oncol; 2005 Mar; 23(9):1921-6. PubMed ID: 15774784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.